Article Details
Retrieved on: 2024-04-23 19:08:11
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
With the decision, the agent became the fourth approved therapy for this patient population, following behind eculizumab (Soliris; Alexion) ...
Article found on: www.neurologylive.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here